Compound protease medicine for treating prostate proliferation and its preparing method

A prostatic hyperplasia and protease technology, applied in the field of biomedicine, can solve the problems of no clinical application and limited effect, and achieve the effect suitable for large-scale production, cost reduction, and definite curative effect

Active Publication Date: 2005-05-18
于文林
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Due to the limited effect of in vivo experiments and the failure to elucidate many...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound protease medicine for treating prostate proliferation and its preparing method
  • Compound protease medicine for treating prostate proliferation and its preparing method
  • Compound protease medicine for treating prostate proliferation and its preparing method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0045] A compound protease drug for the treatment of benign prostatic hyperplasia, which is made of the following raw materials (consumption is parts by weight):

[0046] Hyaluronidase 1.5 Bromelain 0.2 Trypsin 0.5

[0047] Dispase 0.1 Collagenase 0.2 Zhengtamycin 0.02

[0048] Dexamethasone 0.1 Deoxyribonuclease 0.1 Chitosan 0.03

[0049] Terazosin 0.2 Mannitol 0.5 Agarose 0.4

[0050] Triton 0.2

[0051] Its preparation steps are as follows:

[0052] 1. Weigh the above-mentioned raw materials in proportion.

[0053] 2. Dissolve mannitol and agarose in the designated solvents respectively, and sterilize for later use.

[0054] 3. Preparation of Chitosan Gel Sustained Release Agent

[0055] ● Prepare 0.1mol / L dilute acetic acid.

[0056] ●Add 2% chitosan and stir to dissolve it completely.

[0057] ●Use 1mol / L sodium hydroxide to adjust the pH to 5.5--6.0, which is dilute chitosan acetate solution.

[0058] ●Add dilute chitosan acetate solution into terazosin, stir we...

Embodiment 2

[0062] A compound protease drug for the treatment of benign prostatic hyperplasia, which is made of the following raw materials (consumption is parts by weight):

[0063] Hyaluronidase 0.5 Bromelain 1.0 Trypsin 1.5

[0064] Dispase 0.8 Collagenase 0.5 Zhengtamycin 0.02

[0065] Dexamethasone 0.02 Deoxyribonuclease 0.5 Chitosan 0.04

[0066] Terazosin 0.5 Mannitol 1.8 Agarose 0.3

[0067] Triton 0.2

[0068] The preparation steps are the same as in Example 1.

Embodiment 3

[0070] A compound protease drug for the treatment of benign prostatic hyperplasia, which is made of the following raw materials (consumption is parts by weight):

[0071] Hyaluronidase 0.3 Bromelain 0.3 Trypsin 1.5

[0072] Dispase 0.5 Collagenase 1.5 Zhengtamycin 0.02

[0073] Dexamethasone 0.04 Deoxyribonuclease 0.2 Triton 0.5

[0074] Agarose 1.0

[0075] The preparation steps are the same as in Example 1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The compound protease medicine for treating prostate proliferation consists of hyaluronidase, collagenase, desoxyribonuclease and other protease as well as antibiotic, chitosan and other supplementary material. The preparation process includes weighing material in certain proportion; dissolving agarose in solvent and disinfection; preparing chitosan gel and mixing with medicine; adding material into the buffering liquid with calcium and zinc ions, dissolving and mixing; disinfection, detecting endotoxin content, freeze drying into powder in bacteria-free condition and packing. The present invention has high curative effect, low cost, high stability of product and other advantages.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and more specifically relates to a compound protease drug for treating benign prostatic hyperplasia, and also relates to a preparation method of the drug. Background technique [0002] BPH is a common disease that occurs with aging men. With the advancement of medical technology and the improvement of living standards, the life expectancy of our population has been significantly extended. The incidence of benign prostatic hyperplasia is also increasing year by year. According to statistics, at least 80 million patients with benign prostatic hyperplasia need treatment in China. Due to insufficient health resources (equipment, technology), few effective treatment methods, and high medical expenses, most patients can only be tortured by the disease, and they are in a situation where there is no systematic and formal treatment, and the quality of life is worrying. [0003...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/48A61P13/08
Inventor 金化民
Owner 于文林
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap